Review
Biochemistry & Molecular Biology
Krishnasamy naidu gopal Hariprabu, Muthusamy Sathya, Selvaraj Vimalraj
Summary: Tumor angiogenesis is a critical target for cancer treatment, but current anti-angiogenic medicines are ineffective due to compensatory molecular mechanisms. The development of gene-editing technology like CRISPR/Cas9 provides new possibilities for cancer therapy by dissecting carcinogenesis pathways, identifying new biological targets, and potentially arming cancer cells.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
Review
Chemistry, Multidisciplinary
Yuqi Yang, Tianjiao Zhao, Qiaohui Chen, Yumei Li, Zuoxiu Xiao, Yuting Xiang, Boyu Wang, Yige Qiu, Shiqi Tu, Yitian Jiang, Yayun Nan, Qiong Huang, Kelong Ai
Summary: The article discusses the revolutionizing effects of immunotherapy on cancer treatment and the limitations of immunotherapy on ovarian cancer. Nanomedicines have shown promise in improving ovarian cancer treatment by reversing the cold tumor immune microenvironment.
Article
Oncology
Stefania Livia Ciummo, Carlo Sorrentino, Cristiano Fieni, Emma Di Carlo
Summary: Interactions between cancer cells and endothelial cells are crucial for tumor behavior. IL-30, expressed by prostate cancer cells, promotes tumor angiogenesis and progression. This study reveals the involvement of IL-30 in regulating angiogenic, immunoregulatory, and oncogenic gene expression, highlighting its potential as a therapeutic target for prostate cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Kohei Tamura, Takahiro Yoshiba, Suzuyo Takahashi, Akiyo Taneichi, Yuji Takei, Masashi Urabe, Hiroaki Mizukami, Hiroyuki Fujiwara
Summary: VASH2 knockout in ovarian cancer cells enhances chemosensitivity to paclitaxel by reducing tubulin detyrosination and upregulating cyclin B1 expression. This study suggests that targeting VASH2 may be a promising strategy for ovarian cancer treatment by inhibiting angiogenesis and modulating microtubule activity.
Article
Cell Biology
Isadora Carolina Betim Pavan, Fernanda Luisa Basei, Matheus Brandemarte Severino, Ivan Rosa e Silva, Luidy Kazuo Issayama, Mariana Camargo Silva Mancini, Mariana Marcela Gois, Luiz Guilherme Salvino da Silva, Rosangela Maria Neves Bezerra, Fernando Moreira Simabuco, Jorg Kobarg
Summary: NEK6 is a central kinase in developing castration-resistant prostate cancer (CRPC), but the pathways it regulates are unclear. This study found that knocking out NEK6 decreased cell viability, mitochondrial activity, and antioxidant defenses, while increasing intracellular ROS levels, JNK phosphorylation, and DNA damage markers. Exogenous overexpression of NEK6 had the opposite effects. NEK6 also played a role in cell death, cisplatin sensitivity, and nuclear localization of NF-kappa B2. These findings suggest that NEK6 inhibition may be a new therapeutic strategy for CRPC.
Article
Oncology
Fatma A. Abouelnazar, Xiaoxin Zhang, Jiahui Zhang, Maoye Wang, Dan Yu, Xueyan Zang, Jiayin Zhang, Yixin Li, Jing Xu, Qiurong Yang, Yue Zhou, Haozhou Tang, Yanzheng Wang, Jianmei Gu, Xu Zhang
Summary: This study reveals that SALL4 is overexpressed in stomach adenocarcinoma and is associated with tumor progression and poor prognosis. SALL4 regulates VEGF expression at the transcriptional level, thus promoting angiogenesis. Co-delivery of si-SALL4-B and thalidomide using engineered exosomes shows potential in inhibiting cancer angiogenesis.
CANCER CELL INTERNATIONAL
(2023)
Article
Genetics & Heredity
Wei Wang, Fengju Song, Xiangling Feng, Xinlei Chu, Hongji Dai, Jing Tian, Xuan Fang, Fangfang Song, Ben Liu, Lian Li, Xiangchun Li, Yanrui Zhao, Hong Zheng, Kexin Chen
Summary: This study identified 162 target genes enriched in cancer-related pathways through combinatorial analysis of high-resolution contact maps and fine-mapped credible variants from EOC GWAS, with 132 HiChIP targets being identified for EOC causal variants for the first time. More than half of the credible variants were found to be involved in interactions over 185 kb in distance, indicating the importance of long-range transcriptional regulation in the function of GWAS variants in EOC. Additionally, many HiChIP gene targets showed significant differential expressions between normal ovarian and EOC tumor samples, with one target validated through CRISPR-Cas9 deletion experiments.
FRONTIERS IN GENETICS
(2021)
Article
Chemistry, Multidisciplinary
Xue Dong, Pei Pan, Qiu-Ling Zhang, Jing-Jie Ye, Peng Bao, Xuan Zeng, Xian-Zheng Zhang
Summary: This study developed a magnetic nanoparticle-mediated CRISPR/Cas9 system to target and inactivate the Mlh1 gene, resulting in enhanced tumor immunogenicity. In vitro and in vivo experiments demonstrated that this strategy effectively suppressed tumor growth and improved infiltration of CD8(+) T cells and response to immune checkpoint blockade therapy.
Review
Biochemistry & Molecular Biology
Takuya Tsujino, Kazumasa Komura, Teruo Inamoto, Haruhito Azuma
Summary: In recent years, advances in omics technology and CRISPR/Cas9 technology have improved the identification of genes associated with cancer diseases, providing opportunities for the discovery of new therapeutic targets. This knowledge plays a crucial role in clinicians' decision-making regarding patient treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Xuejin Ou, Qizhi Ma, Wei Yin, Xuelei Ma, Zhiyao He
Summary: Immunotherapy has shown great promise in cancer therapy, with the CRISPR/Cas9 system providing a foundation for innovative research and treatment. CRISPR/Cas9 can be used to construct CAR-T cells and TCR-T cells, inhibit immune checkpoint signaling pathways, and screen novel cancer immunotherapy targets.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Cell Biology
Barbora Vesela, Michael Killinger, Kamila Rihova, Petr Benes, Eva Svandova, Adela Kratochvilova, Filip Trcka, Karel Kleparnik, Eva Matalova
Summary: In this study, caspase-8 was eliminated in MC3T3-E1 cells using CRISPR/cas9 technology, and the consequences of caspase-8 deficiency on non-apoptotic pathways in osteoblastic cells were investigated. The results showed that caspase-8 deficiency inhibited osteogenic differentiation and affected the expression of osteogenic genes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Medicine, Research & Experimental
Xiaoyun Tang, Christopher R. Cromwell, Rongzong Liu, Roseline Godbout, Basil P. Hubbard, Todd P. W. McMullen, David N. Brindley
Summary: LPP2 expression is elevated in various malignancies, including breast tumors, hepatocellular carcinoma, pancreatic adenocarcinoma, and melanomas, and is associated with poorer survival. Knocking out LPP2 in breast cancer cells inhibits cell growth by affecting the cell cycle regulators and decreases the expression of c-Myc. Targeting LPP2 may provide a new strategy for reducing c-Myc expression and tumor growth.
Article
Biochemistry & Molecular Biology
Shiro Uchida, Takashi Sugino
Summary: This study identified genes associated with breast cancer progression mechanisms and potential therapeutic targets using bioinformatic tools. It found several genes involved in breast cancer progression and identified potential novel therapeutic targets.
Article
Oncology
Jingjing Zhang, Yun Li, Hua Liu, Jiahui Zhang, Jie Wang, Jia Xia, Yu Zhang, Xiang Yu, Jinyan Ma, Masha Huang, Jiahui Wang, Liangzhe Wang, Qian Li, Rutao Cui, Wen Yang, Yingjie Xu, Weiwei Feng
Summary: This study identified PCMT1 as a critical driver of resistance to detachment-induced apoptosis in ovarian cancer cells. PCMT1 enhanced cell migration, adhesion and spheroid formation through interaction with the ECM protein LAMB3. Treatment with an antibody against extracellular PCMT1 reduced cancer cell invasion and adhesion. PCMT1 was highly expressed in late-stage metastatic tumors, suggesting its potential as a therapeutic target in metastatic ovarian cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Chemistry, Physical
Juhee Lee, Yoo Kyung Kang, Eonju Oh, Juhee Jeong, San Hae Im, Duk Ki Kim, Haeshin Lee, Sang-Gyu Kim, Keehoon Jung, Hyun Jung Chung
Summary: The study presents a cancer gene therapy strategy based on NanoRNP that efficiently blocks the PD-L1 immune checkpoint and induces an antitumor effect in vivo without the need for combination therapy. In vivo results demonstrate that NanoRNP can induce indels in target cells at high frequencies, significantly suppressing tumor growth.
CHEMISTRY OF MATERIALS
(2022)